List view / Grid view
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
In Issue #2 2014: Mass Spectrometry and Stem Cells in-depth focuses, Hot Melt Extrusion, PAT, Excipients, Microbiology plus much more...
In Issue #1 2014: Raman Spectroscopy in-depth focus, Ingredients, LIMS, Kinase, Near Infrared in-depth focus, RNA, Microbiology...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) are colloidal systems of interest for the delivery of poorly water-soluble drugs.
28 January 2014 | By Merck
Merck said it was pleased with the positive discussion of RAGWITEK™ at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration...
21 January 2014 | By kdm communications limited
Spanish biotechnology company Midatech Biogune is taking advantage of Syrris Atlas Potassium reactor systems to produce custom-made functionalized gold nanoparticles for medicinal use...
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
In Issue #6 2013: PAT in-depth focus, Lab Automation, Proteomics, Next Gen Sequencing, Screening in-depth focus, Microbiology...
12 December 2013 | By Merck
GRASTEK is the proposed trade name for the company’s investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis...
18 November 2013 | By Merck
“I am excited by the results seen for MK-3475 to date as a single agent..."
9 November 2013 | By Merck
“Patients in this study who took the investigational Timothy grass sublingual allergy immunotherapy tablet showed a significant improvement in common allergy symptoms..."
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
Read the free digital version of Issue #5 2013 of European Pharmaceutical Review magazine...
